GlassScriptPhysician profile
Neil Robert Wanee
NPI 1730153586
$714.70
in general payments reported to CMS, 2019-2025
13 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2020: $94.28 · 2021: $75.78 · 2022: $124 · 2023: $88.03 · 2024: $31.96 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $246.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $147.30 | 2022-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $107.17 | 2020-2024 | Breztri |
| Indivior INC. | $90.50 | 2019 | |
| Abbvie INC. | $86.68 | 2021-2025 | Vraylar |
| Takeda Pharmaceuticals U.S.A., INC. | $86.49 | 2019-2021 | |
| Radius Health, INC. | $42.72 | 2023-2025 | Tymlos |
| Lilly USA, LLC | $38.16 | 2023-2024 | Jardiance, Mounjaro |
| Daiichi Sankyo INC. | $34.04 | 2022 | |
| Averitas Pharma INC. | $19.81 | 2023 | Qutenza |
| Janssen Pharmaceuticals, INC | $17.34 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.04 | 2021 | |
| Novo Nordisk INC | $14.31 | 2019 | |
| Allergan, INC. | $13.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Wanee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.